NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (Decision date - May 2014)
Do Not Prescribe (DNP):
NICE TA444: Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (Terminated appraisal) (Decision date - June 2017)
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
4: Specifically designated as “hospital only” by product licence or by DH/NICE